CD4+ T-cell recovery after initiation of antiretroviral therapy in a resource-limited setting: A prospective cohort analysis

Antiviral Therapy

Volumn 19, Issue 1, 2014, Pages 31-39

  Kanters, Steve ^a,b   Nachega, Jean ^c,d,e   Funk, Anna ^a   Mukasa, Barbara ^f   Montaner, Julio S G ^g   Ford, Nathan ^h   Bucher, Heiner C ⁱ   Mills, Edward J ^a,g  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c STELLENBOSCH UNIVERSITY   (South Africa)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^f MILDMAY UGANDA   (Uganda)

^g ST PAUL S HOSPITAL   (Canada)

^h Medecins Sans Frontiers   (Switzerland)

ⁱ UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADOLESCENT; ADULT; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; COHORT ANALYSIS; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME; UGANDA;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; MALE; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS;

EID: 84896939952     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2670     Document Type: Article

References (41)

1. Mills EJ, Bakanda C, Birungi J, et al. Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med 2011; 155: 209-216.
2. Mills EJ, Bakanda C, Birungi J, et al. Mortality by baseline CD4 cell count among HIV patients initiating antiretroviral therapy: evidence from a large cohort in Uganda. AIDS 2011; 25:851-855.
3. Autran B. Effects of antiretroviral therapy on immune reconstitution. Antivir Ther 1999; 4 Suppl 3:3-6. (Pubitemid 29512108)
4. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505.
5. Montaner JS, Lima VD, Barrios R, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet 2010; 376:532-539.
6. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. (Accessed 30 August 2012.) Available from http://www.aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl. pdf
7. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012; 308:387-402.
8. Wood R, Lawn SD. Should the CD4 threshold for starting ART be raised? Lancet 2009; 373:1314-1316.
9. Smith CJ, Sabin CA, Youle MS, et al. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy. J Infect Dis 2004; 190:1860-1868. (Pubitemid 39487833)
10. Wood E, Montaner JS. When to initiate HIV antiretroviral therapy: do benefits other than survival deserve greater attention? J Acquir Immune Defic Syndr 2007; 45:131-132. (Pubitemid 46869803)
11. Balestre E, Eholie SP, Lokossue A, et al. Effect of age on immunological response in the first year of antiretroviral therapy in HIV-1-infected adults in West Africa. AIDS 2012; 26:951-957.
12. + T-cell count. J Acquir Immune Defic Syndr 2004; 36:702-713.
13. Lawn SD, Little F, Bekker LG, et al. Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa. AIDS 2009; 23:335-342.
14. Wolbers M, Babiker A, Sabin C, et al. Pretreatment CD4 cell slope and progression to AIDS or death in HIV-infected patients initiating antiretroviral therapy - the CASCADE collaboration: a collaboration of 23 cohort studies. PLoS Med 2010; 7:e1000239.
15. The Opportunistic Infections Project Team of COHERE in EuroCoord. CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE. PLoS Med 2012; 9:e1001194.
16. Lanoy E, May M, Mocroft A, et al. Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements. AIDS 2009; 23:2199-2208.
17. Coetzee D, Hildebrand K, Boulle A, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 2004; 18:887-895. (Pubitemid 38553709)
18. Lawn SD, Myer L, Bekker LG, Wood R. CD4 cell count recovery among HIV-infected patients with very advanced immunodeficiency commencing antiretroviral treatment in sub-Saharan Africa. BMC Infect Dis 2006; 6:59.
19. Kalinkovich A, Weisman Z, Burstein R, Bentwich Z. Standard values of T-lymphocyte subsets in Africa. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17:183-185.
20. Messele T, Abdulkadir M, Fontanet AL, et al. Reduced naive and increased activated CD4 and CD8 cells in healthy adult Ethiopians compared with their Dutch counterparts. Clin Exp Immunol 1999; 115:443-450. (Pubitemid 29130358)
21. Tugume SB, Piwowar EM, Lutalo T, et al. Hematological reference ranges among healthy Ugandans. Clin Diagn Lab Immunol 1995; 2:233-235.
22. Zekeng L, Sadjo A, Meli J, et al. T lymphocyte subset values among healthy Cameroonians. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14:82-83. (Pubitemid 27014409)
23. + T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy. Antivir Ther 2007; 12:889-897.
24. Funk A, Kanters S, Nansubuga M, et al. Cohort Profile: The MUg Observational Cohort. Int J Epidemiol 2012; 41:1594-1594f.
25. Young J, De Geest S, Spirig R, et al. Stable partnership and progression to AIDS or death in HIV infected patients receiving highly active antiretroviral therapy: Swiss HIV cohort study. BMJ 2004; 328:15.
26. Koenker R, Basset G, Jr. Regression quantiles. Econometrica 1978; 46:33-50.
27. Wu Y, Liu Y. Variable selection in quantile regression. Statist Sin 2010; 19:801-817.
28. Koenker R, Machado J. Goodness of fit and related inference processes for quantile regression. JASA 1999; 94:1296-1310.
29. Lipsitz S, Fitzmaurice G, Molenberghs G, Zhao L. Quantile regression methods for longitudinal data with drop-outs: application to CD4 cell counts of patients infected with human immunodeficiency virus. Appl Stat 1997; 46:463-476.
30. Yi G, He W. Median regression models for longitudinal data with dropouts. Biometrics 2009; 65:618-625.
31. Flynn PM, Rudy BJ, Lindsey JC, et al. Long-term observation of adolescents initiating HAART therapy: three-year follow-up. AIDS Res Hum Retroviruses 2007; 23:1208-1214. (Pubitemid 350014760)
32. Nachega JB, Hislop M, Nguyen H, et al. Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in southern Africa. J Acquir Immune Defic Syndr 2009; 51:65-71.
33. 3 or greater. J Acquir Immune Defic Syndr 2007; 45:183-192.
34. Tarwater PM, Margolick JB, Jin J, et al. Increase and plateau of CD4 T-cell counts in the 3(1/2) years after initiation of potent antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 27:168-175. (Pubitemid 32595168)
35. Tumbarello M, Rabagliati R, de Gaetano Donati K, et al. Older age does not influence CD4 cell recovery in HIV-1 infected patients receiving highly active antiretroviral therapy. BMC Infect Dis 2004; 4:46.
36. Viard JP, Mocroft A, Chiesi A, et al. Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study. J Infect Dis 2001; 183:1290-1294. (Pubitemid 32281572)
37. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2010 revision. (Updated 20 July 2010. Accessed 8 April 2013.) Available from http://whqlibdoc.who.int/publications/2010/9789241599764-eng.pdf
38. Mills FP, Ford N, Nachega JB, et al. Earlier initialization of highly active antiretroviral therapy is associated with long term survival and is cost-effective: findings from a deterministic model of a 10-year Ugandan cohort. J Acquir Immune Defic Syndr 2012; 61:364-369.
39. + patients in Uganda. J Acquir Immune Defic Syndr 2013; 63:e23-e27.
40. Bakanda C, Birungi J, Mwesigwa R, et al. Association of aging and survival in a large HIV-infected cohort on antiretroviral therapy. AIDS 2011; 25:701-705.
41. Wachira J, Kimaiyo S, Ndege S, Mamlin J, Braitstein P. What is the impact of home-based HIV counseling and testing on the clinical status of newly enrolled adults in a large HIV care program in Western Kenya? Clin Infect Dis 2012; 54:275-281.